花园生物(300401) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥386,592,882.41, representing a 120.77% increase compared to ¥175,110,442.48 in the same period last year[7]. - Net profit attributable to shareholders was ¥151,152,689.96, a 65.00% increase from ¥91,608,491.56 year-on-year[7]. - Basic earnings per share increased to ¥0.2800, a rise of 64.71% compared to ¥0.1700 in the same period last year[7]. - Operating profit for the quarter was ¥177,090,497.45, up 66.5% from ¥106,353,078.64 year-over-year[35]. - Net profit attributable to the parent company was ¥151,152,689.96, representing a 64.9% increase from ¥91,608,491.56 in the previous year[35]. - Total operating revenue for the first quarter reached ¥386,592,882.41, a significant increase of 120.5% compared to ¥175,110,442.48 in the same period last year[35]. Cash Flow - The net cash flow from operating activities reached ¥245,658,562.83, up 150.25% from ¥98,164,530.79 in the previous year[7]. - Cash flow from operating activities was ¥397,730,897.43, compared to ¥160,042,346.73 in the same period last year, reflecting a growth of 148.5%[39]. - The company recorded a net cash inflow from operating activities, indicating strong operational performance and liquidity[39]. - Total cash inflow from operating activities reached $465,917,742.62, compared to $223,601,614.15 last year, indicating strong operational performance[42]. - Cash outflow from operating activities was $220,259,179.79, up from $125,437,083.36, reflecting increased operational costs[42]. - The company reported a net increase in cash and cash equivalents of $258,493,645.04, contrasting with a decrease of $73,152,540.21 in the previous period[45]. Assets and Liabilities - The company's total assets at the end of Q1 2022 were ¥3,876,256,004.48, reflecting a 9.95% increase from ¥3,525,311,449.31 at the end of the previous year[7]. - Total current assets increased to RMB 1,382,600,961.05 from RMB 1,110,436,101.31, representing a growth of about 24.5%[26]. - Total liabilities rose to ¥1,446,353,382.16, compared to ¥1,246,561,516.95 in the previous year, indicating a growth of 16.1%[34]. - The total liabilities of the company increased, with accounts payable decreasing to RMB 289,926,097.70 from RMB 319,947,181.13, a decline of about 9.4%[26]. - The company's cash and cash equivalents amounted to RMB 761,298,719.13, up from RMB 502,094,136.90 at the beginning of the year, reflecting a growth of approximately 51.5%[23]. Equity and Investments - The total equity attributable to shareholders increased by 6.63% to ¥2,429,902,622.32 from ¥2,278,749,932.36 at the end of the previous year[7]. - The company’s non-current assets totaled RMB 2,493,655,043.43, an increase from RMB 2,414,875,348.00 at the beginning of the year, reflecting a growth of approximately 3.3%[26]. - Research and development expenses surged by 154.44% to ¥16,637,726.66, compared to ¥6,539,022.19 in the same period last year, indicating increased investment in innovation[14]. - The company reported a significant increase in sales expenses, which rose to ¥81,931,930.22, a staggering 1031.48% increase from ¥7,241,133.22 year-on-year, primarily due to higher marketing costs[14]. Shareholder Information - The company reported a total of 8,810,249 shares under lock-up agreements, with a portion of these shares set to unlock at a rate of 25% annually[22]. - The company has a total of 1,840,687 shares held by senior management under lock-up agreements, which will also unlock at a rate of 25% annually[19].